Hypothalamic-pituitary-adrenal axis multiple and organ dysfunction syndrome in critical illness: A special focus on arginine-vasopressin and apelin

Journal of Organ Dysfunction

Volumn 4, Issue 4, 2008, Pages 216-229

  Gallo Payet, Nicole ^a   Roussy, Jean Francois ^a,b   Chagnon, Frederic ^b   Roberge, Claude ^a   Lesur, Olivier ^b,c  

^a Service d'Endocrinologie

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c NONE   (Canada)

Author keywords

Angiotensin II; Apelin; Critical illness; Multiple organ dysfunction syndrome; Sepsis; Vasopressin

Indexed keywords

ANGIOTENSIN II; APELIN; ARGININE; CANDESARTAN; CATECHOLAMINE; CORTICOTROPIN; HYDROCORTISONE; NEUROPEPTIDE; VASOPRESSIN;

ADRENAL CORTEX INSUFFICIENCY; BLOOD LEVEL; BODY FLUID; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CORTICOTROPIN RELEASE; CRITICAL ILLNESS; DRUG EFFICACY; DRUG RELEASE; ENDOTOXEMIA; HEART ARREST; HEART VENTRICLE FIBRILLATION; HEMORRHAGIC SHOCK; HOMEOSTASIS; HUMAN; HYDROCORTISONE RELEASE; HYPOTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOVOLEMIC SHOCK; LOW DRUG DOSE; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; SEPTIC SHOCK; SHOCK; STRESS;

EID: 65249128576     PISSN: 17471060     EISSN: 17471079     Source Type: Journal    
DOI: 10.1080/17471060802339711     Document Type: Review

References (154)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
2. Schroeder S, Wichers M, Klingmuller D, Hofer M, Lehmann LE, von Spiegel T, et al. The hypothalamic-pituitaryadrenal axis of patients with severe sepsis: altered response to corticotropin-releasing hormone. Crit Care Med 2001;29: 310-6.
3. Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877- 87.
4. Parrillo JE. Septic shock--vasopressin, norepinephrine, and urgency. N Engl J Med 2008;358:954-6.
5. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997;336:912-28.
6. Maxime V, Siami S, Annane D. Metabolism modulators in sepsis: the abnormal pituitary response. Crit Care Med 2007;35:S596-601.
7. Betancur C, Borrell J, Guaza C. Cytokine regulation of corticosteroid receptors in the rat hippocampus: effects of interleukin-1, interleukin-6, tumor necrosis factor and lipopolysaccharide. Neuroendocrinology 1995;62:47-54.
8. Imura H, Fukata J. Endocrine-paracrine interaction in communication between the immune and endocrine systems. Activation of the hypothalamic- pituitary-adrenal axis in inflammation. Eur J Endocrinol 1994;130:32-7.
9. Sternberg EM. Neuroendocrine factors in susceptibility to inflammatory disease: focus on the hypothalamic-pituitaryadrenal axis. Horm Res 1995;43:159-61.
10. Elenkov IJ, Chrousos GP. Stress system*organization, physiology and immunoregulation. Neuroimmunomodulation 2006;13:257-67.
11. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993;103:565-75.
12. Thijs LG, Hack CE. Time course of cytokine levels in sepsis. Intensive Care Med 1995;21(Suppl 2):S258-63.
13. Loisa P, Rinne T, Kaukinen S. Adrenocortical function and multiple organ failure in severe sepsis. Acta Anaesthesiol Scand 2002;46:145-51.
14. Abraham E, Singer M. Mechanisms of sepsis-induced organ dysfunction. Crit Care Med 2007;35:2408-16.
15. Marik PE, Zaloga GP. Adrenal insufficiency in the critically ill: a new look at an old problem. Chest 2002;122:1784-96.
16. Annane D, Sebille V, Charpentier C, Bollaert PE, Francois B, Korach JM, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-71.
17. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-55.
18. Melby JC, Spink WW. Comparative studies on adrenal cortical function and cortisol metabolism in healthy adults and in patients with shock due to infection. J Clin Invest 1958;37:1791-8.
19. Parker LN, Levin ER, Lifrak ET. Evidence for adrenocortical adaptation to severe illness. J Clin Endocrinol Metab 1985;60:947-52.
20. Drucker D, McLaughlin J. Adrenocortical dysfunction in acute medical illness. Crit Care Med 1986;14:789-91.
21. Reincke M, Allolio B, Wurth G, Winkelmann W. The hypothalamic-pituitary- adrenal axis in critical illness: response to dexamethasone and corticotropin-releasing hormone. J Clin Endocrinol Metab 1993;77:151-6.
22. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995;332: 1351-62.
23. Aygen B, Inan M, Doganay M, Kelestimur F. Adrenal functions in patients with sepsis. Exp Clin Endocrinol Diabetes 1997;105:182-6.
24. Bouachour G, Tirot P, Gouello JP, Mathieu E, Vincent JF, Alquier P. Adrenocortical function during septic shock. Intensive Care Med 1995;21:57-62.
25. Jurney TH, Cockrell JL Jr, Lindberg JS, Lamiell JM, Wade CE. Spectrum of serum cortisol response to ACTH in ICU patients. Correlation with degree of illness and mortality. Chest 1987;92:292-5.
26. Span LF, Hermus AR, Bartelink AK, Hoitsma AJ, Gimbrere JS, Smals AG, et al. Adrenocortical function: an indicator of severity of disease and survival in chronic critically ill patients. Intensive Care Med 1992;18:93-6.
27. Vermes I, Beishuizen A, Hampsink RM, Haanen C. Dissociation of plasma adrenocorticotropin and cortisol levels in critically ill patients: possible role of endothelin and atrial natriuretic hormone. J Clin Endocrinol Metab 1995;80:1238-42.
28. Sibbald WJ, Short A, Cohen MP, Wilson RF. Variations in adrenocortical responsiveness during severe bacterial infections. Unrecognized adrenocortical insufficiency in severe bacterial infections. Ann Surg 1977;186:29-33.
29. Van der Voort PH, Gerritsen RT, Bakker AJ, Boerma EC, Kuiper MA, de Heide L. HDL-cholesterol level and cortisol response to synacthen in critically ill patients. Intensive Care Med 2003;29:2199-203.
30. Annane D. Corticosteroids for sepsis: controversial forever? J Crit Care 2007;22:329-30.
31. Thomas Z, Fraser GL. An update on the diagnosis of adrenal insufficiency and the use of corticotherapy in critical illness. Ann Pharmacother 2007;41:1456-65.
32. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, et al. N Engl J Med 2008;358:111-24.
33. Gaillard RC, Spinedi E, Chautard T, Pralong FP. Cytokines, leptin, and the hypothalamo-pituitary-adrenal axis. Ann N Y Acad Sci 2000;917:647-57.
34. Bornstein SR, Chrousos GP. Clinical review 104: adrenocorticotropin (ACTH)- and non-ACTH-mediated regulation of the adrenal cortex: neural and immune inputs. J Clin Endocrinol Metab 1999;84:1729-36.
35. Chrousos GP. The stress response and immune function: clinical implications. The 1999 Novera H. Spector Lecture. Ann N Y Acad Sci 2000;917:38-67.
36. Sharshar T, Carlier R, Blanchard A, Feydy A, Gray F, Paillard M, et al. Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 2002;30:497- 500.
37. Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. Chest 2001;120:989-1002.
38. Landry DW, Levin HR, Gallant EM, Ashton RC Jr, Seo S, D'Alessandro D, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997;95: 1122-5.
39. Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D. Circulating vasopressin levels in septic shock. Crit Care Med 2003;31:1752-8.
40. Saavedra JM, Benicky J. Brain and peripheral angiotensin II play a major role in stress. Stress 2007;10:185-93.
41. Tsutsumi K, Saavedra JM. Characterization and development of angiotensin II receptor subtypes (AT1 and AT2) in rat brain. Am J Physiol 1991;261:R209-16.
42. Tsutsumi K, Saavedra JM. Angiotensin-II receptor subtypes in median eminence and basal forebrain areas involved in regulation of pituitary function. Endocrinology 1991;129: 3001-8.
43. Aguilera G, Young WS, Kiss A, Bathia A. Direct regulation of hypothalamic corticotropin-releasing-hormone neurons by angiotensin II. Neuroendocrinology 1995;61:437-44.
44. Jezova D, Ochedalski T, Kiss A, Aguilera G. Brain angiotensin II modulates sympathoadrenal and hypothalamic pituitary adrenocortical activation during stress. J Neuroendocrinol 1998;10:67-72.
45. Armando I, Volpi S, Aguilera G, Saavedra JM. Angiotensin II AT1 receptor blockade prevents the hypothalamic corticotropin- releasing factor response to isolation stress. Brain Res 2007;1142:92-9.
46. Kyrou I, Chrousos GP, Tsigos C. Stress, visceral obesity, and metabolic complications. Ann N Y Acad Sci 2006;1083: 77-110.
47. Aguilera G, Kiss A, Luo X. Increased expression of type 1 angiotensin II receptors in the hypothalamic paraventricular nucleus following stress and glucocorticoid administration. J Neuroendocrinol 1995;7:775-83.
48. Castren E, Saavedra JM. Angiotensin II receptors in paraventricular nucleus, subfornical organ, and pituitary gland of hypophysectomized, adrenalectomized, and vasopressin-deficient rats. Proc Natl Acad Sci U S A 1989;86:725-9.
49. Laesser M, Oi Y, Ewert S, Fandriks L, Aneman A. The angiotensin II receptor blocker candesartan improves survival and mesenteric perfusion in an acute porcine endotoxin model. Acta Anaesthesiol Scand 2004;48:198-204.
50. Dunser MW, Hasibeder WR, Wenzel V, Schwarz S, Ulmer H, Knotzer H, et al. Endocrinologic response to vasopressin infusion in advanced vasodilatory shock. Crit Care Med 2004;32:1266-71.
51. Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med 2004;30:1276-91.
52. Aguilera G, Rabadan-Diehl C. Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul Pept 2000;96:23-9.
53. Guillon G, Balestre MN, Chouinard L, Gallo-Payet N. Involvement of distinct G-proteins in the action of vasopressin on rat glomerulosa cells. Endocrinology 1990;126: 1699-708.
54. Gallo-Payet N, Guillon G. Regulation of adrenocortical function by vasopressin. Horm Metab Res 1998;30:360-7.
55. Grazzini E, Boccara G, Joubert D, Trueba M, Durroux T, Guillon G, et al. Vasopressin regulates adrenal functions by acting through different vasopressin receptor subtypes. Adv Exp Med Biol 1998;449:325-34.
56. Koshimizu TA, Nasa Y, Tanoue A, Oikawa R, Kawahara Y, Kiyono Y, et al. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci U S A 2006;103: 7807-12.
57. Antoni FA. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol 1993;14:76-122.
58. Lolait SJ, O'Carroll AM, Mahan LC, Felder CC, Button DC, Young WS 3rd, et al. Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci U S A 1995;92:6783-7.
59. Lauzier F, Levy B, Lamarre P, Lesur O. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Med 2006;32: 1782-9.
60. Lolait SJ, Stewart LQ, Roper JA, Harrison G, Jessop DS, Young WS 3rd, et al. Attenuated stress response to acute lipopolysaccharide challenge and ethanol administration in vasopressin V1b receptor knockout mice. J Neuroendocrinol 2007;19:543-51.
61. Oelkers W. Hyponatremia and inappropriate secretion of vasopressin (antidiuretic hormone) in patients with hypopituitarism. N Engl J Med 1989;321:492-6.
62. Papanek PE, Raff H. Chronic physiological increases in cortisol inhibit the vasopressin response to hypertonicity in conscious dogs. Am J Physiol 1994;267:R1342-9.
63. Chagnon F, Vaidya V, Bonventre J, Bernard A, Guindi C, Lesur O. Modulation of AQP-2/V2R kidney expression and tubular injury following endotoxin (LPS) challenge. Crit Care Med 2008; In press.
64. Chassin C, Hornef MW, Bens M, Lotz M, Goujon JM, Vimont S, et al. Hormonal control of the renal immune response and antibacterial host defense by arginine vasopressin. J Exp Med 2007;204:2837-52.
65. Erfurth EM, Hedner P, Lundin S, Ekman R. Release of prolactin as well as adrenocorticotropin after administration of arginine-vasopressin to healthy men. Horm Metab Res 1996;28:599-602.
66. Giusti-Paiva A, De Castro M, Antunes-Rodrigues J, Carnio EC. Inducible nitric oxide synthase pathway in the central nervous system and vasopressin release during experimental septic shock. Crit Care Med 2002;30:1306-10.
67. Jochberger S, Mayr VD, Luckner G, Wenzel V, Ulmer H, Schmid S, et al. Serum vasopressin concentrations in critically ill patients. Crit Care Med 2006;34:293-9.
68. Jochberger S, Morgenthaler NG, Mayr VD, Luckner G, Wenzel V, Ulmer H, et al. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab 2006;91:4381-6.
69. Wilson MF, Brackett DJ, Tompkins P, Benjamin B, Archer LT, Hinshaw LB. Elevated plasma vasopressin concentrations during endotoxin and E. coli shock. Adv Shock Res 1981;6:15-26.
70. Brackett DJ, Schaefer CF, Tompkins P, Fagraeus L, Peters LJ, Wilson MF. Evaluation of cardiac output, total peripheral vascular resistance, and plasma concentrations of vasopressin in the conscious, unrestrained rat during endotoxemia. Circ Shock 1985;17:273-84.
71. Carnio EC, Stabile AM, Batalhao ME, Silva JS, Antunes- Rodrigues J, Branco LG, et al. Vasopressin release during endotoxaemic shock in mice lacking inducible nitric oxide synthase. Pflugers Arch 2005;450:390-4.
72. Russell JA. Vasopressin in vasodilatory and septic shock. Curr Opin Crit Care 2007;13:383-91.
73. Landry DW, Oliver JA. The ATP-sensitive K- channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog. J Clin Invest 1992;89:2071-4.
74. Bucher M, Hobbhahn J, Taeger K, Kurtz A. Cytokinemediated downregulation of vasopressin V(1A) receptors during acute endotoxemia in rats. Am J Physiol Regul Integr Comp Physiol 2002;282:R979-84.
75. Morgenthaler NG, Muller B, Struck J, Bergmann A, Redl H, Christ-Crain M. Copeptin, a stable peptide of the arginine vasopressin precursor, is elevated in hemorrhagic and septic shock. Shock 2007;28:219-26.
76. Muller B, Morgenthaler N, Stolz D, Schuetz P, Muller C, Bingisser R, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest 2007;37:145-52.
77. Stolz D, Christ-Crain M, Morgenthaler NG, Leuppi J, Miedinger D, Bingisser R, et al. Copeptin, C-reactive protein, and procalcitonin as prognostic biomarkers in acute exacerbation of COPD. Chest 2007;131:1058-67.
78. Seligman R, Papassotiriou J, Morgenthaler NG, Meisner M, Teixeira PJ. Copeptin, a novel prognostic biomarker in ventilator-associated pneumonia. Crit Care 2008;12:R11.
79. Landry DW, Levin HR, Gallant EM, Seo S, D'Alessandro D, Oz MC, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997;25:1279-82.
80. Barrett LK, Orie NN, Taylor V, Stidwill RP, Clapp LH, Singer M. Differential effects of vasopressin and norepinephrine on vascular reactivity in a long-term rodent model of sepsis. Crit Care Med 2007;35:2337-43.
81. Luckner G, Mayr VD, Jochberger S, Wenzel V, Ulmer H, Hasibeder WR, et al. Comparison of two dose regimens of arginine vasopressin in advanced vasodilatory shock. Crit Care Med 2007;35:2280-5.
82. Morales DL, Garrido MJ, Madigan JD, Helman DN, Faber J, Williams MR, et al. A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass. Ann Thorac Surg 2003;75:926-30.
83. Argenziano M, Choudhri A, Oz M, Rose E, Smith C, Landry D. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997;96(9 Suppl):286-90.
84. Dunser MW, Mayr AJ, Ulmer H, Ritsch N, Knotzer H, Pajk W, et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg 2001;93:7-13.
85. Dunser MW, Mayr AJ, Ulmer H, Knotzer H, Sumann G, Pajk W, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003;107:2313-9.
86. Morales DL, Gregg D, Helman DN, Williams MR, Naka Y, Landry DW, et al. Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock. Ann Thorac Surg 2000;69:102-6.
87. Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 2001;27:1416-21.
88. Malay MB, Ashton JL, Dahl K, Savage EB, Burchell SA, Ashton RC Jr, et al. Heterogeneity of the vasoconstrictor effect of vasopressin in septic shock. Crit Care Med 2004;32:1327-31.
89. Dunser MW, Mayr AJ, Tur A, Pajk W, Barbara F, Knotzer H, et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med 2003;31:1394-8.
90. Van Haren FM, Rozendaal FW, van der Hoeven JG. The effect of vasopressin on gastric perfusion in catecholaminedependent patients in septic shock. Chest 2003;124:2256- 60.
91. Klinzing S, Simon M, Reinhart K, Bredle DL, Meier- Hellmann A. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003;31: 2646-50.
92. Farand P, Hamel M, Lauzier F, Plante GE, Lesur O. Review article: organ perfusion/permeability-related effects of norepinephrine and vasopressin in sepsis. Can J Anaesth 2006;53:934-46.
93. Guzman JA, Rosado AE, Kruse JA. Vasopressin vs norepinephrine in endotoxic shock: systemic, renal, and splanchnic hemodynamic and oxygen transport effects. J Appl Physiol 2003;95:803-9.
94. Dunser MW, Fries DR, Schobersberger W, Ulmer H, Wenzel V, Friesenecker B, et al. Does arginine vasopressin influence the coagulation system in advanced vasodilatory shock with severe multiorgan dysfunction syndrome? Anesth Analg 2004;99:201-6.
95. Filep J, Rosenkranz B. Mechanism of vasopressin-induced platelet aggregation. Thromb Res 1987;45:7-15.
96. Levy B, Vallee C, Lauzier F, Plante GE, Mansart A, Mallie JP, et al. Comparative effects of vasopressin, norepinephrine, and L-canavanine, a selective inhibitor of inducible nitric oxide synthase, in endotoxic shock. Am J Physiol Heart Circ Physiol 2004;287:H209-15.
97. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002;96:576-82.
98. Leone M, Boyle WA. Decreased vasopressin responsiveness in vasodilatory septic shock-like conditions. Crit Care Med 2006;34:1126-30.
99. Sun Q, Dimopoulos G, Nguyen DN, Tu Z, Nagy N, Hoang AD, et al. Low-dose vasopressin in the treatment of septic shock in sheep. Am J Respir Crit Care Med 2003;168:481-6.
100. Ertmer C, Bone HG, Morelli A, Van Aken H, Erren M, Lange M, et al. Methylprednisolone reverses vasopressin hyporesponsiveness in ovine endotoxemia. Shock 2007;27: 281-8.
101. Karmazyn M, Manku MS, Horrobin DF. Changes of vascular reactivity induced by low vasopressin concentrations: interactions with cortisol and lithium and possible involvement of prostaglandins. Endocrinology 1978;102: 1230-6.
102. Aboab J, Polito A, Orlikowski D, Sharshar T, Castel M, Annane D. Hydrocortisone effects on cardiovascular variability in septic shock: a spectral analysis approach. Crit Care Med 2008;36:1481-6.
103. Callewaere C, Banisadr G, Desarmenien MG, Mechighel P, Kitabgi P, Rostene WH, et al. The chemokine SDF-1/ CXCL12 modulates the firing pattern of vasopressin neurons and counteracts induced vasopressin release through CXCR4. Proc Natl Acad Sci U S A 2006;103:8221-6.
104. Morales D, Madigan J, Cullinane S, Chen J, Heath M, Oz M, et al. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock. Circulation 1999; 100:226-9.
105. Stroumpoulis K, Xanthos T, Rokas G, Kitsou V, Papadimitriou D, Serpetinis I, et al. Vasopressin and epinephrine in the treatment of cardiac arrest: an experimental study. Crit Care 2008;12:R40.
106. Mayr V, Luckner G, Jochberger S, Wenzel V, Ulmer H, Pajk W, et al. Arginine vasopressin in advanced cardiovascular failure during the post-resuscitation phase after cardiac arrest. Resuscitation 2007;72:35-44.
107. Adrie C, Laurent I, Monchi M, Cariou A, Dhainaou JF, Spaulding C. Postresuscitation disease after cardiac arrest: a sepsis-like syndrome? Curr Opin Crit Care 2004;10:208-12.
108. Huang L, Tang W. Vasopressor agents: old and new components. Curr Opin Crit Care 2004;10:183-7.
109. Reaux-Le Goazigo A, Alvear-Perez R, Zizzari P, Epelbaum J, Bluet-Pajot MT, Llorens-Cortes C. Cellular localization of apelin and its receptor in the anterior pituitary: evidence for a direct stimulatory action of apelin on ACTH release. Am J Physiol Endocrinol Metab 2007;292:E7-15.
110. Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem 2000;74:34-41.
111. Japp AG, Newby DE. The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. Biochem Pharmacol 2008;75:1882-92.
112. Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998;251:471-6.
113. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther 2005;107:198-211.
114. Katugampola S, Davenport A. Emerging roles for orphan Gprotein- coupled receptors in the cardiovascular system. Trends Pharmacol Sci 2003;24:30-5.
115. O'Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993;136:355-60.
116. Habata Y, Fujii R, Hosoya M, Fukusumi S, Kawamata Y, Hinuma S, et al. Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim Biophys Acta 1999;1452:25-35.
117. Hosoya M, Kawamata Y, Fukusumi S, Fujii R, Habata Y, Hinuma S, et al. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem 2000;275:21061-7.
118. Reaux A, De Mota N, Skultetyova I, Lenkei Z, El Messari S, Gallatz K, et al. Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J Neurochem 2001; 77:1085-96.
119. Lee DK, George SR, O'Dowd BF. Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity. Trends Pharmacol Sci 2006;27: 190-4.
120. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, et al. Hydrolysis of biological peptides by human angiotensinconverting enzyme-related carboxypeptidase. J Biol Chem 2002;277:14838-43.
121. Burrell LM, Johnston CI, Tikellis C, Cooper ME. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab 2004;15:166-9.
122. De Falco M, De Luca L, Onori N, Cavallotti I, Artigiano F, Esposito V, et al. Apelin expression in normal human tissues. In Vivo 2002;16:333-6.
123. De Mota N, Lenkei Z, Llorens-Cortes C. Cloning, pharmacological characterization and brain distribution of the rat apelin receptor. Neuroendocrinology 2000;72:400-7.
124. Kawamata Y, Habata Y, Fukusumi S, Hosoya M, Fujii R, Hinuma S, et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta 2001;1538:162-71.
125. Medhurst AD, Jennings CA, Robbins MJ, Davis RP, Ellis C, Winborn KY, et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem 2003;84:1162-72.
126. O'Carroll AM, Selby TL, Palkovits M, Lolait SJ. Distribution of mRNA encoding B78/apj, the rat homologue of the human APJ receptor, and its endogenous ligand apelin in brain and peripheral tissues. Biochim Biophys Acta 2000; 1492:72-80.
127. Reaux A, Gallatz K, Palkovits M, Llorens-Cortes C. Distribution of apelin-synthesizing neurons in the adult rat brain. Neuroscience 2002;113:653-62.
128. Brailoiu GC, Dun SL, Yang J, Ohsawa M, Chang JK, Dun NJ. Apelin-immunoreactivity in the rat hypothalamus and pituitary. Neurosci Lett 2002;327:193-7.
129. Jaszberenyi M, Bujdoso E, Telegdy G. Behavioral, neuroendocrine and thermoregulatory actions of apelin-13. Neuroscience 2004;129:811-6.
130. Taheri S, Murphy K, Cohen M, Sujkovic E, Kennedy A, Dhillo W, et al. The effects of centrally administered apelin- 13 on food intake, water intake and pituitary hormone release in rats. Biochem Biophys Res Commun 2002;291: 1208-12.
131. Renner U, Pagotto U, Arzt E, Stalla GK. Autocrine and paracrine roles of polypeptide growth factors, cytokines and vasogenic substances in normal and tumorous pituitary function and growth: a review. Eur J Endocrinol 1996;135: 515-32.
132. Schwartz J, Cherny R. Intercellular communication within the anterior pituitary influencing the secretion of hypophysial hormones. Endocr Rev 1992;13:453-75.
133. Edinger AL, Hoffman TL, Sharron M, Lee B, Yi Y, Choe W, et al. An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 1998;72:7934-40.
134. Devic E, Rizzoti K, Bodin S, Knibiehler B, Audigier Y. Amino acid sequence and embryonic expression of msr/apj, the mouse homolog of Xenopus X-msr and human APJ. Mech Dev 1999;84:199-203.
135. Ishida J, Hashimoto T, Hashimoto Y, Nishiwaki S, Iguchi T, Harada S, et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem 2004;279:26274-9.
136. Cohen RA, Vanhoutte PM. Endothelium-dependent hyperpolarization. Beyond nitric oxide and cyclic GMP. Circulation 1995;92:3337-49.
137. Katugampola SD, Maguire JJ, Matthewson SR, Davenport AP. [(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol 2001;132:1255-60.
138. Szokodi I, Tavi P, Foldes G, Voutilainen-Myllyla S, Ilves M, Tokola H, et al. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002;91:434-40.
139. Dai T, Ramirez-Correa G, Gao WD. Apelin increases contractility in failing cardiac muscle. Eur J Pharmacol 2006;553:222-8.
140. Ashley EA, Powers J, Chen M, Kundu R, Finsterbach T, Caffarelli A, et al. The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res 2005;65:73-82.
141. Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA. Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 2006;8:355-60.
142. Francia P, Salvati A, Balla C, De Paolis P, Pagannone E, Borro M, et al. Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin. Eur J Heart Fail 2007;9:306-9.
143. Goetze JP, Rehfeld JF, Carlsen J, Videbaek R, Andersen CB, Boesgaard S, et al. Apelin: a new plasma marker of cardiopulmonary disease. Regul Pept 2006;133:134-8.
144. Evora PR, Pearson PJ, Schaff HV. Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery. V1-receptor-mediated production of nitric oxide. Chest 1993;103:1241-5.
145. Daviaud D, Boucher J, Gesta S, Dray C, Guigne C, Quilliot D, et al. TNFalpha up-regulates apelin expression in human and mouse adipose tissue. FASEB J 2006;20:1528-30.
146. Llorens-Cortes C, Beaudet A. Apelin, a neuropeptide that counteracts vasopressin secretion. Med Sci (Paris) 2005;21: 741-6 (in French).
147. Berry MF, Pirolli TJ, Jayasankar V, Burdick J, Morine KJ, Gardner TJ, et al. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 2004;110:II187-93.
148. Chen MM, Ashley EA, Deng DX, Tsalenko A, Deng A, Tabibiazar R, et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 2003;108:1432-9.
149. Charles CJ, Rademaker MT, Richards AM. Apelin-13 induces a biphasic haemodynamic response and hormonal activation in normal conscious sheep. J Endocrinol 2006;189:701-10.
150. Cheng X, Cheng XS, Pang CC. Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur J Pharmacol 2003;470: 171-5.
151. Sorhede Winzell M, Magnusson C, Ahren B. The apj receptor is expressed in pancreatic islets and its ligand, apelin, inhibits insulin secretion in mice. Regul Pept 2005; 131:12-7.
152. Tang SY, Xie H, Yuan LQ, Luo XH, Huang J, Cui RR, et al. Apelin stimulates proliferation and suppresses apoptosis of mouse osteoblastic cell line MC3T3-E1 via JNK and PI3-K/ Akt signaling pathways. Peptides 2007;28:708-18.
153. Xie H, Yuan LQ, Luo XH, Huang J, Cui RR, Guo LJ, et al. Apelin suppresses apoptosis of human osteoblasts. Apoptosis 2007;12:247-54.
154. Han S, Wang G, Qiu S, de la Motte C, Wang HQ, Gomez G, et al. Increased colonic apelin production in rodents with experimental colitis and in humans with IBD. Regul Pept 2007;142:131-7.